Back to results
US 2015/0177259 A1Published application
Methods for treatment of cardiovascular disease
AssigneeThe Brigham and Women's Hospital, Inc.
InventorRichard T. Lee
Life of this patent
Estimating the term…
Abstract
This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
Claims12
1-7. (canceled)
A method for monitoring a cardiovascular condition in a subject over time, the method comprising:
- (a) performing an immunoassay to determine a first level of soluble ST2 protein in a biological sample from a subject having a cardiovascular condition at a first time point;
- (b) comparing the first level of soluble ST2 protein to a predetermined value;
- (c) identifying a subject having an elevated first level of soluble ST2 protein as compared to the predetermined value;
- (d) preforming an immunoassay(s) to determine a level of soluble ST2 protein in one or more additional samples from the identified subject over time;
- and
- (e) identifying a subject having an elevated first level(s) of soluble ST2 protein as determined in (d) as compared to the first level of soluble ST2 protein as having a progressing cardiovascular condition.
3 more elements
9-36. (canceled)
A method for monitoring a subject having myocardial infarction, stroke, or heart failure over time, the method comprising:
- (a) performing an immunoassay to determine a first level of soluble ST2 protein in a biological sample from a subject having myocardial infarction, stroke, or heart failure at a first time point;
- (b) comparing the first level of soluble ST2 protein to a predetermined value;
- (c) identifying a subject having an elevated first level of soluble ST2 protein as compared to the predetermined value;
- (d) performing an immunoassay(s) to determine a level of soluble ST2 protein in one or more additional biological samples from the identified subject over time;
- and
- (e) identifying a subject having an elevated level(s) of soluble ST2 protein as determined in (d) as compared to the first level of soluble ST2 protein as having a progressing myocardial infarction, stroke, or heart failure.
3 more elements
Dependencies are inferred from the claim text.